@article{10.11648/j.crj.20231104.15,
  author = {Shamsun Nahar and Nazir Uddin Mollah and Md Saidul Haque and Md Jamal Uddin and Sarwar Alam and Faruk Ahammad and Khursheda Akhter and Shejuti Sharmin and Afsana Sharmin Anika and Nasrin Akhter},
  title = {Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status},
  journal = {Cancer Research Journal},
  volume = {11},
  number = {4},
  pages = {156-160},
  doi = {10.11648/j.crj.20231104.15},
  url = {https://doi.org/10.11648/j.crj.20231104.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20231104.15},
  abstract = {Introduction: Worldwide, breast cancer is the second most common cause of death. The occurrence of breast cancer is roughly 2.3 million women of all ages worldwide. Both the normal breast cells and some breast cancer cells have the receptors that attach to the estrogen and progesterone hormone and play vital roles for normal and even abnormal growth of breast cells. The aim of this study was to evaluate the prognosis of breast cancer in relation with receptor status. Methods: This prospective observational study was carried out in the Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh during the period from December 2011 to December 2021. In total 100 breast cancer patients of several stages and grades were enrolled in this study as study subjects. Proper written consents were taken from all the participants before data collection. All data were processed, analyzed and disseminated by using MS Excel and SPSS version 25.0 as per need. Result: In this study, among total 100 cases, estrogen receptors were analyzed in 88 cases; among them in majority (86%), positive estrogen receptors were found whereas negative receptors were found in 14% cases. Progesterone receptors were analyzed in 85 cases; among them in majority (69%), positive progesterone receptors were found whereas negative receptors were found in 31% cases. HER 2 receptors were analyzed in 52 cases; among them in majority (67%), negative HER 2 receptors were found whereas positive receptors were found in 33% cases. highest death (12%) occurred in patients with ER-/PR-. In contrast, no death was seen in ER+/PR+ patients. In comparing the estrogen receptor status among participants, we did not find any significant correlation considering the stages or grades of carcinoma; the P values were >0.05. Conclusion: This study concluded that, compared to women of breast cancer with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality and distant metastasis. Receptor status of breast cancer may be considered as potential indicator for proper management of patients with breast cancer. Preliminary diagnosis and treatment of breast cancers have a certain survival advantage. Thus, we should need to assess the hormone receptor status for every patient before commencing treatment. To get robust data, multicenter studies are in great need of policymakers to interpret the demonstrable scenario and to take necessary steps towards mitigating this problem.
},
 year = {2023}
}

Copy | Download

TY  - JOUR
T1  - Prognosis of Breast Cancer in Relation with Estrogen-Progesterone and HER-2 Receptor Status
AU  - Shamsun Nahar
AU  - Nazir Uddin Mollah
AU  - Md Saidul Haque
AU  - Md Jamal Uddin
AU  - Sarwar Alam
AU  - Faruk Ahammad
AU  - Khursheda Akhter
AU  - Shejuti Sharmin
AU  - Afsana Sharmin Anika
AU  - Nasrin Akhter
Y1  - 2023/12/14
PY  - 2023
N1  - https://doi.org/10.11648/j.crj.20231104.15
DO  - 10.11648/j.crj.20231104.15
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 156
EP  - 160
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20231104.15
AB  - Introduction: Worldwide, breast cancer is the second most common cause of death. The occurrence of breast cancer is roughly 2.3 million women of all ages worldwide. Both the normal breast cells and some breast cancer cells have the receptors that attach to the estrogen and progesterone hormone and play vital roles for normal and even abnormal growth of breast cells. The aim of this study was to evaluate the prognosis of breast cancer in relation with receptor status. Methods: This prospective observational study was carried out in the Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh during the period from December 2011 to December 2021. In total 100 breast cancer patients of several stages and grades were enrolled in this study as study subjects. Proper written consents were taken from all the participants before data collection. All data were processed, analyzed and disseminated by using MS Excel and SPSS version 25.0 as per need. Result: In this study, among total 100 cases, estrogen receptors were analyzed in 88 cases; among them in majority (86%), positive estrogen receptors were found whereas negative receptors were found in 14% cases. Progesterone receptors were analyzed in 85 cases; among them in majority (69%), positive progesterone receptors were found whereas negative receptors were found in 31% cases. HER 2 receptors were analyzed in 52 cases; among them in majority (67%), negative HER 2 receptors were found whereas positive receptors were found in 33% cases. highest death (12%) occurred in patients with ER-/PR-. In contrast, no death was seen in ER+/PR+ patients. In comparing the estrogen receptor status among participants, we did not find any significant correlation considering the stages or grades of carcinoma; the P values were >0.05. Conclusion: This study concluded that, compared to women of breast cancer with ER+/PR+ tumors, women with ER+/PR-, ER-/PR+, or ER-/PR- tumors experienced higher risks of mortality and distant metastasis. Receptor status of breast cancer may be considered as potential indicator for proper management of patients with breast cancer. Preliminary diagnosis and treatment of breast cancers have a certain survival advantage. Thus, we should need to assess the hormone receptor status for every patient before commencing treatment. To get robust data, multicenter studies are in great need of policymakers to interpret the demonstrable scenario and to take necessary steps towards mitigating this problem.

VL  - 11
IS  - 4
ER  - 

Copy | Download